Showing 3061-3070 of 5771 results for "".
- Opus Genetics Receives $1.7 Million in Funding from the Foundation Fighting Blindness to Support Two Preclinical Programshttps://modernod.com/news/opus-genetics-receives-17-million-in-funding-from-the-foundation-fighting-blindness-to-support-two-preclinical-programs/2482320/Gene therapy company Opus Genetics announced it has received $1.7 million in project-based funding from the Foundation Fighting Blindness to help advance two preclinical candidate programs. “Opus is immensely grateful for the generous support from the Foundation Fighting Blin
- Beacon Therapeutics Treats First Patient in VISTA Trial of AGTC-501 for XLRPhttps://modernod.com/news/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501/2482319/Beacon Therapeutics announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec). VISTA is a global randomized, controlled, masked, multicenter pivotal study evaluating the efficacy, safety, and
- Skye Fails Phase 2 Glaucoma Trial; Shifts Focus to Obesityhttps://modernod.com/news/skye-fails-phase-2-glaucoma-trial-shifts-focus-to-obesity/2482317/Skye Bioscience announced that its phase 2a clinical trial of SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering IOP. As a result, Skye intends to discontinue clinical development and spendi
- Melt Pharmaceuticals Doses First Patient in Phase 3 Program of MELT-300 Opioid-Free Sedationhttps://modernod.com/news/melt-pharmaceuticals-doses-first-patient-in-pivotal-phase-3-program-of-melt-300-opioid-free-sedation/2482312/Melt Pharmaceuticals announced that the first patient has been dosed in its phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingual
- Eversight Partners with LighTopTech to Improve Imaging Modalities for Eye Tissueshttps://modernod.com/news/eversight-partners-with-lightoptech-to-improve-imaging-modalities-for-eye-tissues/2482310/Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings. Financial terms of the deal were not disclosed. As part of th
- Azura Ophthalmics Enrolls First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with MGDhttps://modernod.com/news/azura-ophthalmics-enrolls-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-mgd/2482307/Azura Ophthalmics announced that the first patient has been enrolled in the ASTRO study—a phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of meibomian gland dysfunction (MGD). "AZR-MD-001 has already dem
- Aurion Biotech Completes Enrollment In Phase 1/2 Clinical Trial of Allogeneic Cell Therapy Candidatehttps://modernod.com/news/aurion-biotech-completes-enrollment-in-phase-12-clinical-trial-of-allogeneic-cell-therapy-candidate/2482306/Aurion Biotech announced that it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “Aurion Biotech is delighted that both enrollm
- Bausch + Lomb Launches Blink NutriTears Nutritional Supplement for Dry Eyes in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nutritears-nutritional-supplement-for-dry-eyes-in-the-us/2482305/Bausch + Lomb announced the US launch of Blink NutriTears, an over-the-counter supplement designed to target the key root causes of dry eyes, promote healthy tear production, and provide relief of eye dryness symptoms in as little as 2 to 4 weeks.[1,2]
- LambdaVision Closing of Seed Round to Advance Artificial Retina Preclinical Studieshttps://modernod.com/news/lambdavision-closing-of-seed-round-to-advance-artificial-retina-preclinical-studies/2482302/LambdaVision, which is developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round. The proceeds will be used to fund LambdaVision’s GMP manufacturing scale up and critical IN
- Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eyehttps://modernod.com/news/nordic-pharma-launches-lacrifill-canalicular-gel-for-dry-eye/2482301/Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, a novel therapy for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system